InMed Pharmaceuticals Inc
NASDAQ:INM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
InMed Pharmaceuticals Inc
Total Liabilities
InMed Pharmaceuticals Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
InMed Pharmaceuticals Inc
NASDAQ:INM
|
Total Liabilities
$1.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
15%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Total Liabilities
$26.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Total Liabilities
CA$348m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
35%
|
|
|
Cronos Group Inc
TSX:CRON
|
Total Liabilities
$103.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
47%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Total Liabilities
$106.3m
|
CAGR 3-Years
57%
|
CAGR 5-Years
93%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Total Liabilities
CA$279m
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
45%
|
|
InMed Pharmaceuticals Inc
Glance View
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. The company is specializing in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. The company is also developing an integrated biosynthesis-based manufacturing approach, called IntegraSyn, for synthesizing pharmaceutical-grade cannabinoids, for potential use in product candidates. The firm's two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.
See Also
What is InMed Pharmaceuticals Inc's Total Liabilities?
Total Liabilities
1.6m
USD
Based on the financial report for Dec 31, 2025, InMed Pharmaceuticals Inc's Total Liabilities amounts to 1.6m USD.
What is InMed Pharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
15%
Over the last year, the Total Liabilities growth was -31%. The average annual Total Liabilities growth rates for InMed Pharmaceuticals Inc have been -15% over the past three years , -17% over the past five years , and 15% over the past ten years .
